戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 cal antipsychotic, but not by haloperidol, a typical antipsychotic.
2 iological trait unaffected by treatment with typical antipsychotics.
3 ctioning in schizophrenic subjects receiving typical antipsychotics.
4 e seven studies that compared clozapine to a typical antipsychotic, a meta-analysis was performed to
5 os were calculated for users of atypical and typical antipsychotics adjusting for known cataractogeni
6 rt-term benefits with the continued use of a typical antipsychotic after achieving remission from an
7 rmine the benefits of the continued use of a typical antipsychotic agent following remission from an
8 on of D2 receptor affinity comparable to the typical antipsychotic agent haloperidol and a 5-HT2A/D2
9 ipsychotic drugs, by definition, differ from typical antipsychotic agents in producing significantly
10 eficial therapeutic profile of atypical over typical antipsychotic agents include 1) simultaneous ant
11                                              Typical antipsychotic and atypical antipsychotic subject
12  drug washout after chronic treatment with a typical antipsychotic and before prospective treatment w
13                               Haloperidol, a typical antipsychotic and D2R blocker, reduced AMPH hype
14 85 schizophrenia patients (56 medicated with typical antipsychotics and 29 unmedicated), 83 of their
15  again in comparison with patients receiving typical antipsychotics and untreated control subjects.
16 iving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control su
17 ms during the first week of treatment with a typical antipsychotic are unlikely to respond to a 4-wee
18 oints, in comparison with patients receiving typical antipsychotics as well as untreated healthy cont
19 es when treated with clozapine rather than a typical antipsychotic, as reflected by Brief Psychiatric
20                            One compound, the typical antipsychotic azaperone, improved the motility o
21 y required failure in trials of at least two typical antipsychotics before initiation of an atypical
22                                              Typical antipsychotics can cause disabling side effects.
23 death in elderly patients with dementia, the typical antipsychotics carry an even higher risk of deat
24  psychoses often involves treatment with the typical antipsychotic drug and dopamine D2 receptor anta
25 , significantly potentiated the ability of a typical antipsychotic drug haloperidol, a D2 receptor an
26                       Whereas haloperidol, a typical antipsychotic drug that is primarily a dopamine
27 actions of UNC9975 and transformed it into a typical antipsychotic drug with a high propensity to ind
28 ellular D2LR signaling mediated effects of a typical antipsychotic drug, haloperidol, in inducing cat
29 idal side effects associated with the use of typical antipsychotic drugs (e.g., haloperidol).
30                                 Atypical and typical antipsychotic drugs alter GSK-3 activity, as do
31 e, five subjects who were being treated with typical antipsychotic drugs and five subjects who were b
32  and other medications, they do suggest that typical antipsychotic drugs and lithium have contrasting
33                                              Typical antipsychotic drugs are widely thought to allevi
34                                              Typical antipsychotic drugs do not improve this deficit
35 aired visual contrast detection, those given typical antipsychotic drugs exhibited higher visual cont
36                                     Users of typical antipsychotic drugs have an increased risk of se
37 ntipsychotic drugs as compared with users of typical antipsychotic drugs was 1.14 (95% CI, 0.93 to 1.
38                                              Typical antipsychotic drugs, such as haloperidol and chl
39                               Among users of typical antipsychotic drugs, the incidence-rate ratios i
40 s) are more expensive than first-generation (typical) antipsychotics (FGAs) but are perceived to be m
41 d effect sizes for baseline treatment with a typical antipsychotic (>6 months treatment), drug washou
42                Chronic administration of the typical antipsychotic haloperidol (1 mg/kg) and the atyp
43 the atypical antipsychotic clozapine and the typical antipsychotic haloperidol could modulate the eff
44 ifically, antagonism of D2R signaling by the typical antipsychotic haloperidol induces parkinsonism i
45 c, as it was not observed with exposure to a typical antipsychotic, haloperidol or an atypical antips
46 ted that clozapine exhibits superiority over typical antipsychotics in terms of both efficacy (as mea
47  than G-protein-dependent signaling, whereas typical antipsychotics inhibit both pathways with simila
48          In contrast, the patients receiving typical antipsychotic medications had dramatically lower
49 ransdermal patch and with either atypical or typical antipsychotic medications.
50 ic episode treated with the combination of a typical antipsychotic (perphenazine) and a mood stabiliz
51 xia) and that several psychotic symptoms are typical antipsychotic resistant and atypical antipsychot
52 olinergic interneurons and the mechanisms of typical antipsychotic side effects.
53 The effect size for clozapine, compared with typical antipsychotics, suggests that the drug-washout l
54 tected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparin
55 sychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated cont

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。